One Community at a Time: Enabling Early Lung Cancer Detection Across the U.S.
Bristol Myers Squibb Foundation (BMS Foundation) is expanding its initiatives to improve lung cancer screening access across underserved communities in the United States. The foundation has awarded several significant grants, including $6.8 million for the QUILS™ program in Mississippi and Nevada, building on the success of Kentucky LEADS which achieved a 10% decline in late-stage diagnoses. Additionally, a $2.5 million grant was given to UCLA Health to lead CAL-PALS, targeting improved screening access in Los Angeles County.
The foundation is also collaborating with the U.S. Department of Veterans Affairs on the MAS-EXPAND study to research lung cancer risk factors in veterans. These initiatives aim to increase early detection rates, which can improve five-year survival rates from 4% to 55% when lung cancer is discovered early enough for surgical removal.
La Fondazione Bristol Myers Squibb (BMS Foundation) sta ampliando le sue iniziative per migliorare l'accesso allo screening del cancro ai polmoni nelle comunità svantaggiate negli Stati Uniti. La fondazione ha assegnato diversi finanziamenti significativi, tra cui 6,8 milioni di dollari per il programma QUILS™ in Mississippi e Nevada, basandosi sul successo di Kentucky LEADS, che ha raggiunto una diminuzione del 10% nelle diagnosi in fase avanzata. Inoltre, è stato dato un finanziamento di 2,5 milioni di dollari alla UCLA Health per guidare CAL-PALS, mirato a migliorare l'accesso agli screening nella Contea di Los Angeles.
La fondazione sta inoltre collaborando con il Dipartimento degli Affari dei Veterani degli Stati Uniti per lo studio MAS-EXPAND, volto a ricercare i fattori di rischio del cancro ai polmoni nei veterani. Queste iniziative mirano ad aumentare i tassi di rilevamento precoce, che possono migliorare i tassi di sopravvivenza a cinque anni dal 4% al 55% quando il cancro ai polmoni viene scoperto in tempo utile per la rimozione chirurgica.
La Fundación Bristol Myers Squibb (BMS Foundation) está ampliando sus iniciativas para mejorar el acceso a la detección del cáncer de pulmón en comunidades desatendidas de los Estados Unidos. La fundación ha otorgado varias subvenciones significativas, incluyendo $6.8 millones para el programa QUILS™ en Mississippi y Nevada, construyendo sobre el éxito de Kentucky LEADS, que logró una disminución del 10% en los diagnósticos en etapa avanzada. Además, se otorgó una subvención de $2.5 millones a UCLA Health para liderar CAL-PALS, con el objetivo de mejorar el acceso a la detección en el Condado de Los Ángeles.
La fundación también está colaborando con el Departamento de Asuntos de Veteranos de los EE. UU. en el estudio MAS-EXPAND para investigar los factores de riesgo del cáncer de pulmón en veteranos. Estas iniciativas tienen como objetivo aumentar las tasas de detección temprana, lo que puede mejorar las tasas de supervivencia a cinco años del 4% al 55% cuando el cáncer de pulmón se descubre lo suficientemente pronto para su extracción quirúrgica.
브리스톨 마이어스 스퀴브 재단 (BMS Foundation)은 미국의 소외된 지역 사회에서 폐암 검진 접근성을 개선하기 위한 이니셔티브를 확장하고 있습니다. 이 재단은 미시시피와 네바다의 QUILS™ 프로그램에 680만 달러를 포함한 여러 중요한 보조금을 수여했으며, 켄터키 LEADS의 성공을 기반으로 하여 후기 진단을 10% 감소시켰습니다. 또한, 로스앤젤레스 카운티에서의 검진 접근성 개선을 목표로 UCLA Health에 250만 달러의 보조금이 제공되었습니다.
이 재단은 또한 미국 재향군인청과 협력하여 재향군인의 폐암 위험 요소를 연구하는 MAS-EXPAND 연구를 진행하고 있습니다. 이러한 이니셔티브는 조기 발견율을 높이는 것을 목표로 하며, 폐암이 수술적 제거가 가능할 만큼 조기에 발견될 경우 5년 생존율을 4%에서 55%로 개선할 수 있습니다.
La Fondation Bristol Myers Squibb (BMS Foundation) étend ses initiatives pour améliorer l'accès au dépistage du cancer du poumon dans les communautés mal desservies des États-Unis. La fondation a accordé plusieurs subventions significatives, dont 6,8 millions de dollars pour le programme QUILS™ dans le Mississippi et le Nevada, s'appuyant sur le succès de Kentucky LEADS qui a réalisé une diminution de 10 % des diagnostics à un stade avancé. De plus, une subvention de 2,5 millions de dollars a été accordée à UCLA Health pour diriger CAL-PALS, visant à améliorer l'accès au dépistage dans le comté de Los Angeles.
La fondation collabore également avec le Département des Anciens Combattants des États-Unis sur l'étude MAS-EXPAND pour rechercher les facteurs de risque du cancer du poumon chez les vétérans. Ces initiatives visent à augmenter les taux de détection précoce, ce qui peut améliorer les taux de survie à cinq ans de 4 % à 55 % lorsque le cancer du poumon est découvert suffisamment tôt pour être retiré chirurgicalement.
Die Bristol Myers Squibb Stiftung (BMS Foundation) erweitert ihre Initiativen zur Verbesserung des Zugangs zu Lungenkrebs-Screenings in benachteiligten Gemeinschaften in den Vereinigten Staaten. Die Stiftung hat mehrere bedeutende Zuschüsse vergeben, darunter 6,8 Millionen Dollar für das QUILS™-Programm in Mississippi und Nevada, das auf dem Erfolg von Kentucky LEADS aufbaut, das eine 10%ige Verringerung der späten Diagnosen erzielte. Zudem wurde UCLA Health ein Zuschuss von 2,5 Millionen Dollar gewährt, um CAL-PALS zu leiten, das darauf abzielt, den Zugang zu Screenings im Los Angeles County zu verbessern.
Die Stiftung arbeitet auch mit dem US-Verteidigungsministerium an der MAS-EXPAND-Studie zusammen, um Risikofaktoren für Lungenkrebs bei Veteranen zu erforschen. Diese Initiativen zielen darauf ab, die Frühentdeckungsraten zu erhöhen, was die fünfjährige Überlebensrate von 4% auf 55% verbessern kann, wenn Lungenkrebs früh genug für eine chirurgische Entfernung entdeckt wird.
- Kentucky LEADS program achieved 10% decline in late-stage lung cancer diagnoses
- $6.8 million grant allocated for QUILS™ program expansion to Mississippi and Nevada
- $2.5 million grant awarded to UCLA Health for CAL-PALS initiative
- Current lung cancer screening rates remain low, with Los Angeles County at only 5-6%
Originally published on Bristol Myers Squibb News & Perspectives
NORTHAMPTON, MA / ACCESSWIRE / December 18, 2024 / This year brings renewed hope to the fight against lung cancer because the public health community has the tools they need to turn the tide - and they are already seeing the results in action.
Early detection through screening is key to improving lung cancer survivorship - when lung cancer is discovered early enough to be surgically removed before spreading, a patient's chance of surviving five years jumps from
The Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organization, is working to change that. Through an expanding network of innovative, community-based programs and research initiatives, the BMS Foundation aims to increase access to screening in underserved communities and better understand who may be at risk. Together, these efforts are designed to improve health outcomes and enable more patients to benefit from early detection.
"Early detection saves lives. But far too many Americans, especially people in underserved communities, face barriers to accessing lung cancer screening," said Catharine Grimes, president of the BMS Foundation. "Through our capacity-building lung cancer screening grants, we are empowering local healthcare providers and researchers, improving health outcomes and bringing this life-saving modality to communities across the country."
One example of the BMS Foundation's current work builds on the remarkable success of Kentucky LEADS (Lung Cancer Education, Awareness, Detection and Survivorship). Launched in 2014 with a
With a new
"Our experience in Kentucky has taught us that improving lung cancer screening rates requires a collaborative, quality-focused approach," said Jennifer Redmond Knight, co-principal investigator of Kentucky LEADS Collaborative and an assistant professor in the UK College of Public Health. "This funding will allow us to apply what we've learned in Kentucky to help create targeted solutions for Mississippi and Nevada, potentially setting a new standard for lung cancer screening nationwide."
Building on successful efforts to expand screening access in rural communities, the BMS Foundation is also addressing similar challenges in high-risk urban areas. In Los Angeles County, where screening rates hover at just 5
"Unfortunately, many high-risk individuals face barriers to accessing lung cancer screening and our hope is that this initiative will demonstrate how a high-resource institution like UCLA can help community hospitals not only save more lives in the short term but also pave the way for lasting improvements in lung cancer outcomes across the region and entire state of California," said Dr. Drew Moghanaki, professor and chief of thoracic oncology in the Department of Radiation Oncology and principal investigator for the grant.
Beyond expanding access to screening, the BMS Foundation, in collaboration with the U.S. Department of Veterans Affairs, is supporting groundbreaking research to better understand who may be at risk for lung cancer and inform future guidelines. Led by Dr. Jennifer Lewis, an assistant professor at Vanderbilt University Medical Center's Division of Hematology-Oncology, the MAS-EXPAND study will examine whether veterans aged 50 and older who have smoked at least 100 cigarettes and have additional risk factors, including military exposures, should be considered a high-risk population for lung cancer.
This comprehensive approach - from implementing proven screening programs to investigating screening criteria - demonstrates the BMS Foundation's commitment to advancing early detection for at-risk populations.
Through strategic partnerships and sustainable solutions, the BMS Foundation is helping to write a new chapter in the fight against lung cancer, one community at a time.
About the Bristol Myers Squibb Foundation
The Bristol Myers Squibb Foundation, an independent charitable organization, works to improve global health by empowering local communities and health systems to create lasting impact in regions of the world that are underserved and heavily burdened. The BMS Foundation embraces innovative approaches that have the potential to reshape healthcare systems by engaging in partnerships that build capacity in the geographies where they work. Through these strategic partnerships, the BMS Foundation can transform how care is delivered and help to ensure improved health now and in the future. For more information, visit bms.com/foundation.
Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com
SOURCE: Bristol Myers Squibb Company
View the original press release on accesswire.com
FAQ
What is the success rate of early lung cancer detection according to BMY Foundation research?
How much funding did BMY Foundation provide for the Kentucky LEADS program?
What is the current lung cancer screening rate in Los Angeles County?
What is the QUILS program funded by BMY Foundation?
What is the CAL-PALS initiative supported by BMY Foundation?
